FDA Needs Earlier Reports On Sponsors’ Ties To Trial Investigators, OIG Says
This article was originally published in The Gray Sheet
Executive Summary
Industry sponsors of device and drug studies should disclose to FDA all of their financial relationships with the researchers before the trials even begin, according to a January 2009 1report by HHS' Office of Inspector General